• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Doxorubicin Hydrochloride Liposome Injection Availability

[10/8/2013] 

FDA is providing information on the availability of doxorubicin hydrochloride liposome injection to supply the U.S. market.

Doxil® (doxorubicin hydrochloride liposome injection) is distributed by Janssen Products, LP and has been manufactured under contract by Ben Venue Laboratories, Inc. On September 25, 2013, Janssen notified healthcare professionals of an interruption of supply of Doxil resulting from manufacturing issues at Ben Venue Laboratories. On October 3, 2013, Ben Venue Laboratories announced their plans to cease all manufacturing by the end of 2013.

Sun Pharma Global has confirmed to FDA that there are sufficient supplies of its doxorubicin hydrochloride liposome injection, a generic product that is therapeutically equivalent to Janssen’s Doxil, to cover the U.S. market. Please contact your wholesaler or the following customer service numbers to obtain product: 

Sun Pharma Global FZE
(Caraco Pharmaceutical, U.S. distributor)
1-888-835-2237
 

2 mg/mL; 10 mL vial
(NDC 47335-049-40)


2 mg/ml; 25 mL vial
(NDC 47335-050-40)

Janssen Products, LP
1-800-526-7736
(1-800-JANSSEN) 
Doxil 2 mg/mL, Janssen Products, LP
2 mg/mL, 10 mL (20 mg) vial (NDC 59676-0960-01)
 

Doxil® is indicated for the treatment of ovarian cancer with disease progression after platinum-based chemotherapy, AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy, and multiple myeloma in combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.

Sun Pharma Global’s doxorubicin hydrochloride liposome injection is indicated for the treatment of ovarian cancer with disease progression after platinum-based chemotherapy and for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).